The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis
There are uncertainties about the epidemic patterns of HDV infection and its contribution to the burden of liver disease. We estimated the global prevalence of HDV infection and explored its contribution to the development of cirrhosis and hepatocellular carcinoma (HCC) among HBsAg-positive people....
Uložené v:
| Vydané v: | Journal of hepatology Ročník 73; číslo 3; s. 523 - 532 |
|---|---|
| Hlavní autori: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Netherlands
Elsevier B.V
01.09.2020
Elsevier |
| Predmet: | |
| ISSN: | 0168-8278, 1600-0641, 1600-0641 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | There are uncertainties about the epidemic patterns of HDV infection and its contribution to the burden of liver disease. We estimated the global prevalence of HDV infection and explored its contribution to the development of cirrhosis and hepatocellular carcinoma (HCC) among HBsAg-positive people.
We searched Pubmed, EMBASE and Scopus for studies reporting on total or IgG anti-HDV among HBsAg-positive people. Anti-HDV prevalence was estimated using a binomial mixed model, weighting for study quality and population size. The population attributable fraction (PAF) of HDV to cirrhosis and HCC among HBsAg-positive people was estimated using random effects models.
We included 282 studies, comprising 376 population samples from 95 countries, which together tested 120,293 HBsAg-positive people for anti-HDV. The estimated anti-HDV prevalence was 4.5% (95% CI 3.6–5.7) among all HBsAg-positive people and 16.4% (14.6–18.6) among those attending hepatology clinics. Worldwide, 0.16% (0.11–0.25) of the general population, totalling 12.0 (8.7–18.7) million people, were estimated to be anti-HDV positive. Prevalence among HBsAg-positive people was highest in Mongolia, the Republic of Moldova and countries in Western and Middle Africa, and was higher in injecting drug users, haemodialysis recipients, men who have sex with men, commercial sex workers, and those with HCV or HIV. Among HBsAg-positive people, preliminary PAF estimates of HDV were 18% (10–26) for cirrhosis and 20% (8–33) for HCC.
An estimated 12 million people worldwide have experienced HDV infection, with higher prevalence in certain geographic areas and populations. HDV is a significant contributor to HBV-associated liver disease. More quality data are needed to improve the precision of burden estimates.
We combined all available studies to estimate how many people with hepatitis B also have hepatitis D, a viral infection that only affects people with hepatitis B. About 1 in 22 people with hepatitis B also have hepatitis D, increasing to 1 in 6 when considering people with liver disease. Hepatitis D may cause about 1 in 6 of the cases of cirrhosis and 1 in 5 of the cases of liver cancer that occur in people with hepatitis B. Hepatitis D is an important contributor to the global burden of liver disease.
[Display omitted]
•HDV infection is common among HBsAg-positive people worldwide.•Among HBsAg-positive people, estimated HDV prevalence is 4.5% (95% CI 3.6–5.7).•HDV prevalence in HBsAg-positive hepatology clinic attendees is 16.4% (14.6–18.6).•HDV prevalence is higher in people who inject drugs and who have HCV or HIV.•HDV causes an estimated 18% of cirrhosis and 20% of HCC associated with hepatitis B. |
|---|---|
| AbstractList | There are uncertainties about the epidemic patterns of HDV infection and its contribution to the burden of liver disease. We estimated the global prevalence of HDV infection and explored its contribution to the development of cirrhosis and hepatocellular carcinoma (HCC) among HBsAg-positive people.
We searched Pubmed, EMBASE and Scopus for studies reporting on total or IgG anti-HDV among HBsAg-positive people. Anti-HDV prevalence was estimated using a binomial mixed model, weighting for study quality and population size. The population attributable fraction (PAF) of HDV to cirrhosis and HCC among HBsAg-positive people was estimated using random effects models.
We included 282 studies, comprising 376 population samples from 95 countries, which together tested 120,293 HBsAg-positive people for anti-HDV. The estimated anti-HDV prevalence was 4.5% (95% CI 3.6-5.7) among all HBsAg-positive people and 16.4% (14.6-18.6) among those attending hepatology clinics. Worldwide, 0.16% (0.11-0.25) of the general population, totalling 12.0 (8.7-18.7) million people, were estimated to be anti-HDV positive. Prevalence among HBsAg-positive people was highest in Mongolia, the Republic of Moldova and countries in Western and Middle Africa, and was higher in injecting drug users, haemodialysis recipients, men who have sex with men, commercial sex workers, and those with HCV or HIV. Among HBsAg-positive people, preliminary PAF estimates of HDV were 18% (10-26) for cirrhosis and 20% (8-33) for HCC.
An estimated 12 million people worldwide have experienced HDV infection, with higher prevalence in certain geographic areas and populations. HDV is a significant contributor to HBV-associated liver disease. More quality data are needed to improve the precision of burden estimates.
We combined all available studies to estimate how many people with hepatitis B also have hepatitis D, a viral infection that only affects people with hepatitis B. About 1 in 22 people with hepatitis B also have hepatitis D, increasing to 1 in 6 when considering people with liver disease. Hepatitis D may cause about 1 in 6 of the cases of cirrhosis and 1 in 5 of the cases of liver cancer that occur in people with hepatitis B. Hepatitis D is an important contributor to the global burden of liver disease. There are uncertainties about the epidemic patterns of HDV infection and its contribution to the burden of liver disease. We estimated the global prevalence of HDV infection and explored its contribution to the development of cirrhosis and hepatocellular carcinoma (HCC) among HBsAg-positive people.BACKGROUND AND AIMSThere are uncertainties about the epidemic patterns of HDV infection and its contribution to the burden of liver disease. We estimated the global prevalence of HDV infection and explored its contribution to the development of cirrhosis and hepatocellular carcinoma (HCC) among HBsAg-positive people.We searched Pubmed, EMBASE and Scopus for studies reporting on total or IgG anti-HDV among HBsAg-positive people. Anti-HDV prevalence was estimated using a binomial mixed model, weighting for study quality and population size. The population attributable fraction (PAF) of HDV to cirrhosis and HCC among HBsAg-positive people was estimated using random effects models.METHODSWe searched Pubmed, EMBASE and Scopus for studies reporting on total or IgG anti-HDV among HBsAg-positive people. Anti-HDV prevalence was estimated using a binomial mixed model, weighting for study quality and population size. The population attributable fraction (PAF) of HDV to cirrhosis and HCC among HBsAg-positive people was estimated using random effects models.We included 282 studies, comprising 376 population samples from 95 countries, which together tested 120,293 HBsAg-positive people for anti-HDV. The estimated anti-HDV prevalence was 4.5% (95% CI 3.6-5.7) among all HBsAg-positive people and 16.4% (14.6-18.6) among those attending hepatology clinics. Worldwide, 0.16% (0.11-0.25) of the general population, totalling 12.0 (8.7-18.7) million people, were estimated to be anti-HDV positive. Prevalence among HBsAg-positive people was highest in Mongolia, the Republic of Moldova and countries in Western and Middle Africa, and was higher in injecting drug users, haemodialysis recipients, men who have sex with men, commercial sex workers, and those with HCV or HIV. Among HBsAg-positive people, preliminary PAF estimates of HDV were 18% (10-26) for cirrhosis and 20% (8-33) for HCC.RESULTSWe included 282 studies, comprising 376 population samples from 95 countries, which together tested 120,293 HBsAg-positive people for anti-HDV. The estimated anti-HDV prevalence was 4.5% (95% CI 3.6-5.7) among all HBsAg-positive people and 16.4% (14.6-18.6) among those attending hepatology clinics. Worldwide, 0.16% (0.11-0.25) of the general population, totalling 12.0 (8.7-18.7) million people, were estimated to be anti-HDV positive. Prevalence among HBsAg-positive people was highest in Mongolia, the Republic of Moldova and countries in Western and Middle Africa, and was higher in injecting drug users, haemodialysis recipients, men who have sex with men, commercial sex workers, and those with HCV or HIV. Among HBsAg-positive people, preliminary PAF estimates of HDV were 18% (10-26) for cirrhosis and 20% (8-33) for HCC.An estimated 12 million people worldwide have experienced HDV infection, with higher prevalence in certain geographic areas and populations. HDV is a significant contributor to HBV-associated liver disease. More quality data are needed to improve the precision of burden estimates.CONCLUSIONSAn estimated 12 million people worldwide have experienced HDV infection, with higher prevalence in certain geographic areas and populations. HDV is a significant contributor to HBV-associated liver disease. More quality data are needed to improve the precision of burden estimates.We combined all available studies to estimate how many people with hepatitis B also have hepatitis D, a viral infection that only affects people with hepatitis B. About 1 in 22 people with hepatitis B also have hepatitis D, increasing to 1 in 6 when considering people with liver disease. Hepatitis D may cause about 1 in 6 of the cases of cirrhosis and 1 in 5 of the cases of liver cancer that occur in people with hepatitis B. Hepatitis D is an important contributor to the global burden of liver disease.LAY SUMMARYWe combined all available studies to estimate how many people with hepatitis B also have hepatitis D, a viral infection that only affects people with hepatitis B. About 1 in 22 people with hepatitis B also have hepatitis D, increasing to 1 in 6 when considering people with liver disease. Hepatitis D may cause about 1 in 6 of the cases of cirrhosis and 1 in 5 of the cases of liver cancer that occur in people with hepatitis B. Hepatitis D is an important contributor to the global burden of liver disease. There are uncertainties about the epidemic patterns of HDV infection and its contribution to the burden of liver disease. We estimated the global prevalence of HDV infection and explored its contribution to the development of cirrhosis and hepatocellular carcinoma (HCC) among HBsAg-positive people. We searched Pubmed, EMBASE and Scopus for studies reporting on total or IgG anti-HDV among HBsAg-positive people. Anti-HDV prevalence was estimated using a binomial mixed model, weighting for study quality and population size. The population attributable fraction (PAF) of HDV to cirrhosis and HCC among HBsAg-positive people was estimated using random effects models. We included 282 studies, comprising 376 population samples from 95 countries, which together tested 120,293 HBsAg-positive people for anti-HDV. The estimated anti-HDV prevalence was 4.5% (95% CI 3.6–5.7) among all HBsAg-positive people and 16.4% (14.6–18.6) among those attending hepatology clinics. Worldwide, 0.16% (0.11–0.25) of the general population, totalling 12.0 (8.7–18.7) million people, were estimated to be anti-HDV positive. Prevalence among HBsAg-positive people was highest in Mongolia, the Republic of Moldova and countries in Western and Middle Africa, and was higher in injecting drug users, haemodialysis recipients, men who have sex with men, commercial sex workers, and those with HCV or HIV. Among HBsAg-positive people, preliminary PAF estimates of HDV were 18% (10–26) for cirrhosis and 20% (8–33) for HCC. An estimated 12 million people worldwide have experienced HDV infection, with higher prevalence in certain geographic areas and populations. HDV is a significant contributor to HBV-associated liver disease. More quality data are needed to improve the precision of burden estimates. We combined all available studies to estimate how many people with hepatitis B also have hepatitis D, a viral infection that only affects people with hepatitis B. About 1 in 22 people with hepatitis B also have hepatitis D, increasing to 1 in 6 when considering people with liver disease. Hepatitis D may cause about 1 in 6 of the cases of cirrhosis and 1 in 5 of the cases of liver cancer that occur in people with hepatitis B. Hepatitis D is an important contributor to the global burden of liver disease. [Display omitted] •HDV infection is common among HBsAg-positive people worldwide.•Among HBsAg-positive people, estimated HDV prevalence is 4.5% (95% CI 3.6–5.7).•HDV prevalence in HBsAg-positive hepatology clinic attendees is 16.4% (14.6–18.6).•HDV prevalence is higher in people who inject drugs and who have HCV or HIV.•HDV causes an estimated 18% of cirrhosis and 20% of HCC associated with hepatitis B. • HDV infection is common among HBsAg-positive people worldwide. • Among HBsAg-positive people, estimated HDV prevalence is 4.5% (95% CI 3.6–5.7). • HDV prevalence in HBsAg-positive hepatology clinic attendees is 16.4% (14.6–18.6). • HDV prevalence is higher in people who inject drugs and who have HCV or HIV. • HDV causes an estimated 18% of cirrhosis and 20% of HCC associated with hepatitis B. |
| Author | Henrion, Marc Y.R. Giorgi, Emanuele Stockdale, Alexander J. Kyomuhangi, Irene de Martel, Catherine Hutin, Yvan Geretti, Anna Maria Kreuels, Benno |
| Author_xml | – sequence: 1 givenname: Alexander J. orcidid: 0000-0002-5828-3328 surname: Stockdale fullname: Stockdale, Alexander J. organization: Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom – sequence: 2 givenname: Benno orcidid: 0000-0003-2315-8954 surname: Kreuels fullname: Kreuels, Benno organization: College of Medicine, Blantyre, Malawi – sequence: 3 givenname: Marc Y.R. orcidid: 0000-0003-1242-839X surname: Henrion fullname: Henrion, Marc Y.R. organization: Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi – sequence: 4 givenname: Emanuele orcidid: 0000-0003-0640-181X surname: Giorgi fullname: Giorgi, Emanuele organization: Centre for Health Informatics, Computing, and Statistics, University of Lancaster, Lancaster, United Kingdom – sequence: 5 givenname: Irene orcidid: 0000-0002-2797-015X surname: Kyomuhangi fullname: Kyomuhangi, Irene organization: Centre for Health Informatics, Computing, and Statistics, University of Lancaster, Lancaster, United Kingdom – sequence: 6 givenname: Catherine orcidid: 0000-0002-3642-277X surname: de Martel fullname: de Martel, Catherine organization: International Agency for Research on Cancer, Lyon, France – sequence: 7 givenname: Yvan surname: Hutin fullname: Hutin, Yvan organization: World Health Organization, Geneva, Switzerland – sequence: 8 givenname: Anna Maria surname: Geretti fullname: Geretti, Anna Maria email: geretti@liverpool.ac.uk organization: Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32335166$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkc1uEzEUhS1URNPAC7BAXrKZ4J8Zj10hpKr8SpVYkA0ry-O50zh47GBPgvL2eJQWQRdlYy98vnOt-12gsxADIPSSkhUlVLzZrrYb2K0YYWRF6hUh8glaUEFIRURNz9CihGQlWSvP0UXOW0IIJ6p-hs4547yhQizQ9_UG8K2PnfF4l-BgPAQLOA64VJvJTS7j9_jg0j5jFwawk4vhEn875gnG8m5xgRz8wib0eITJVCYYf8wuP0dPB-MzvLi7l2j98cP6-nN18_XTl-urm8o2LZuq2kouGjH0CgQ0VklLZU-VGYwynDXSCKCCdbzuBiv7vuvaVlkKA2NGtbLjS_TuVLvbdyP0FsKUjNe75EaTjjoap_99CW6jb-NBtzWXqhxL9PquIMWfe8iTHl224L0JEPdZM66a8g9FVIm--nvWnyH36ywBeQrYFHNOMGjrJjOvrIx2XlOiZ3N6q2dzejanSa2LuYKyB-h9-6PQ2xMEZcFFQ9LZullg71JRpfvoHscvH-DWu-Cs8T_g-D_4N20jx-U |
| CitedBy_id | crossref_primary_10_1007_s12072_023_10575_0 crossref_primary_10_1016_j_gastrohep_2022_09_009 crossref_primary_10_3390_pathogens13100859 crossref_primary_10_4254_wjh_v16_i4_640 crossref_primary_10_3390_pathogens14010101 crossref_primary_10_3389_fmed_2023_1086012 crossref_primary_10_1111_jvh_13939 crossref_primary_10_1016_j_gastha_2022_12_002 crossref_primary_10_3390_biom15010121 crossref_primary_10_13105_wjma_v9_i2_139 crossref_primary_10_1111_jvh_13811 crossref_primary_10_3390_v17081100 crossref_primary_10_1016_j_gastha_2023_06_014 crossref_primary_10_1038_s41392_024_02072_z crossref_primary_10_1007_s00108_024_01671_w crossref_primary_10_3748_wjg_v27_i24_3530 crossref_primary_10_1007_s41669_023_00466_3 crossref_primary_10_3390_v13040555 crossref_primary_10_1016_j_meegid_2024_105671 crossref_primary_10_1038_s41598_021_87975_5 crossref_primary_10_20514_2226_6704_2025_15_3_216_225 crossref_primary_10_1111_liv_15253 crossref_primary_10_3389_fmicb_2025_1509890 crossref_primary_10_3390_v13101912 crossref_primary_10_1002_ueg2_12564 crossref_primary_10_3389_fmicb_2025_1553129 crossref_primary_10_1007_s11894_023_00901_9 crossref_primary_10_1080_15321819_2022_2141578 crossref_primary_10_1016_j_jiph_2023_08_011 crossref_primary_10_3389_fmolb_2025_1598784 crossref_primary_10_1111_liv_15579 crossref_primary_10_1111_jvh_13834 crossref_primary_10_1111_jvh_13831 crossref_primary_10_3390_pathogens13050362 crossref_primary_10_1111_jvh_13950 crossref_primary_10_1016_j_jcv_2021_104870 crossref_primary_10_1038_s41419_025_07838_z crossref_primary_10_36290_vnl_2023_104 crossref_primary_10_12998_wjcc_v13_i26_104421 crossref_primary_10_1016_j_jhep_2021_01_014 crossref_primary_10_1111_hiv_13581 crossref_primary_10_1016_j_jhep_2021_01_010 crossref_primary_10_1111_liv_15467 crossref_primary_10_1080_20477724_2022_2047551 crossref_primary_10_1016_j_ijid_2023_12_014 crossref_primary_10_1055_a_2181_3162 crossref_primary_10_1055_a_2181_3046 crossref_primary_10_1007_s00103_022_03486_2 crossref_primary_10_1016_j_jhep_2024_05_001 crossref_primary_10_1055_a_2181_3345 crossref_primary_10_3390_v17091220 crossref_primary_10_1097_TP_0000000000004641 crossref_primary_10_1111_liv_16006 crossref_primary_10_3390_ijms232415973 crossref_primary_10_1186_s12985_025_02897_2 crossref_primary_10_1016_j_aohep_2023_101175 crossref_primary_10_1371_journal_ppat_1011749 crossref_primary_10_1097_COH_0000000000000760 crossref_primary_10_1016_j_cgh_2024_09_025 crossref_primary_10_20344_amp_19527 crossref_primary_10_1186_s12985_025_02907_3 crossref_primary_10_1016_j_jcv_2025_105828 crossref_primary_10_3390_v13050788 crossref_primary_10_3748_wjg_v27_i28_4603 crossref_primary_10_1186_s13690_021_00693_2 crossref_primary_10_7759_cureus_10855 crossref_primary_10_1016_j_jhep_2023_03_017 crossref_primary_10_1016_j_ijid_2023_11_005 crossref_primary_10_1016_j_cld_2023_05_010 crossref_primary_10_1016_j_cld_2023_05_011 crossref_primary_10_3390_vaccines10111928 crossref_primary_10_3390_v15081695 crossref_primary_10_3390_v16101568 crossref_primary_10_1097_JCMA_0000000000001073 crossref_primary_10_1080_14728214_2023_2205639 crossref_primary_10_4274_vhd_galenos_2022_2021_8_1 crossref_primary_10_3390_gidisord4040026 crossref_primary_10_1111_ctr_14971 crossref_primary_10_3390_v13050778 crossref_primary_10_4254_wjh_v16_i3_300 crossref_primary_10_3350_cmh_2022_0084 crossref_primary_10_3390_livers4040040 crossref_primary_10_3389_fmicb_2022_838382 crossref_primary_10_1002_ueg2_12494 crossref_primary_10_3390_v15010091 crossref_primary_10_1016_j_cld_2023_05_007 crossref_primary_10_1001_jama_2023_23242 crossref_primary_10_1016_j_cld_2023_05_008 crossref_primary_10_1016_j_jhep_2024_06_031 crossref_primary_10_7759_cureus_85200 crossref_primary_10_1186_s12985_025_02908_2 crossref_primary_10_1111_liv_70065 crossref_primary_10_1111_liv_70186 crossref_primary_10_3390_v17010052 crossref_primary_10_1002_aid2_13308 crossref_primary_10_1111_liv_15389 crossref_primary_10_2807_1560_7917_ES_2025_30_29_2500015 crossref_primary_10_1111_apt_16408 crossref_primary_10_1111_liv_15387 crossref_primary_10_1111_apt_17971 crossref_primary_10_1097_HEP_0000000000001092 crossref_primary_10_2217_fmb_2021_0177 crossref_primary_10_1097_QAD_0000000000003024 crossref_primary_10_1017_exp_2022_13 crossref_primary_10_3390_math10203917 crossref_primary_10_1038_s41598_023_49819_2 crossref_primary_10_1038_s41598_025_91765_8 crossref_primary_10_1016_j_jhepr_2025_101495 crossref_primary_10_1038_s44319_024_00236_0 crossref_primary_10_1186_s12879_022_07444_w crossref_primary_10_1111_liv_15519 crossref_primary_10_1111_liv_15638 crossref_primary_10_1111_liv_15515 crossref_primary_10_3390_v14020198 crossref_primary_10_1099_jgv_0_001978 crossref_primary_10_1111_jvh_13779 crossref_primary_10_1111_jvh_13899 crossref_primary_10_1111_jvh_13777 crossref_primary_10_1186_s13561_024_00528_0 crossref_primary_10_1111_jvh_13891 crossref_primary_10_3390_microorganisms11122895 crossref_primary_10_1016_j_clinre_2021_101677 crossref_primary_10_3390_cancers16223723 crossref_primary_10_1097_HEP_0000000000000663 crossref_primary_10_1111_liv_15408 crossref_primary_10_1111_liv_15529 crossref_primary_10_1111_apt_16945 crossref_primary_10_1016_j_lanmic_2025_101076 crossref_primary_10_5501_wjv_v14_i2_102673 crossref_primary_10_3390_v15081687 crossref_primary_10_1111_liv_70008 crossref_primary_10_3390_diseases13060168 crossref_primary_10_1111_liv_15770 crossref_primary_10_2152_jmi_72_47 crossref_primary_10_3390_biomedicines13020280 crossref_primary_10_2147_JHC_S384751 crossref_primary_10_1002_lt_26543 crossref_primary_10_1007_s13237_025_00587_6 crossref_primary_10_1016_j_cgh_2024_08_036 crossref_primary_10_1111_jvh_13783 crossref_primary_10_1038_s41598_024_77737_4 crossref_primary_10_3390_v16060825 crossref_primary_10_1016_j_jhep_2025_03_018 crossref_primary_10_1111_liv_70151 crossref_primary_10_1111_liv_15855 crossref_primary_10_3390_life13051115 crossref_primary_10_1111_jvh_13797 crossref_primary_10_1007_s11901_023_00606_7 crossref_primary_10_1016_j_jhep_2022_08_041 crossref_primary_10_1016_j_cgh_2024_08_046 crossref_primary_10_1097_HC9_0000000000000746 crossref_primary_10_1055_a_2123_1730 crossref_primary_10_1097_HEP_0000000000000642 crossref_primary_10_1111_liv_15745 crossref_primary_10_1111_liv_70026 crossref_primary_10_3389_fmed_2023_1108543 crossref_primary_10_1186_s12879_023_08524_1 crossref_primary_10_3389_fpubh_2022_1099571 crossref_primary_10_3390_v15071509 crossref_primary_10_1016_j_coph_2021_03_008 crossref_primary_10_1016_j_drugpo_2021_103134 crossref_primary_10_1155_2024_2364031 crossref_primary_10_2478_jtim_2024_0015 crossref_primary_10_1038_s41575_020_0332_6 crossref_primary_10_3390_cancers16081505 crossref_primary_10_1056_NEJMoa2213429 crossref_primary_10_14309_ajg_0000000000002810 crossref_primary_10_1111_liv_15679 crossref_primary_10_1111_liv_15795 crossref_primary_10_1111_liv_70336 crossref_primary_10_1186_s40798_022_00517_9 crossref_primary_10_3390_v13050830 crossref_primary_10_1038_s41575_020_00361_w crossref_primary_10_3390_pathogens10101227 crossref_primary_10_52645_MJHS_2024_4_04 crossref_primary_10_1016_j_ijid_2021_10_052 crossref_primary_10_1128_jvi_01280_25 crossref_primary_10_1186_s12954_024_01117_4 crossref_primary_10_3389_fpubh_2024_1437502 crossref_primary_10_1007_s12072_023_10629_3 crossref_primary_10_1080_07388551_2022_2030295 crossref_primary_10_1016_j_jhep_2024_03_005 crossref_primary_10_1016_j_ijmmb_2021_11_003 crossref_primary_10_4103_njcp_njcp_27_24 crossref_primary_10_1111_liv_15447 crossref_primary_10_1016_j_gastha_2025_100743 crossref_primary_10_1111_jvh_13621 crossref_primary_10_1111_jvh_13987 crossref_primary_10_1111_jvh_13620 crossref_primary_10_3390_v15091791 crossref_primary_10_1016_j_jhepr_2025_101471 crossref_primary_10_1186_s41687_025_00903_3 crossref_primary_10_1111_liv_15417 crossref_primary_10_14309_ajg_0000000000001947 crossref_primary_10_1111_trf_18238 crossref_primary_10_3390_v13091799 crossref_primary_10_3748_wjg_v29_i38_5395 crossref_primary_10_3389_fcimb_2024_1382029 crossref_primary_10_3390_ijerph17186650 crossref_primary_10_1016_j_jhep_2020_05_019 crossref_primary_10_1111_jvh_13874 crossref_primary_10_3389_fimmu_2023_1287367 crossref_primary_10_1097_MEG_0000000000002489 crossref_primary_10_1016_j_antiviral_2024_106062 crossref_primary_10_3390_v16060817 crossref_primary_10_1097_HEP_0000000000000722 crossref_primary_10_1111_apt_16807 crossref_primary_10_1080_23744235_2024_2434887 crossref_primary_10_1016_j_jhep_2020_06_037 crossref_primary_10_1016_j_jhep_2020_06_039 crossref_primary_10_1007_s15036_021_2291_3 crossref_primary_10_1111_liv_15424 crossref_primary_10_1111_jvh_13889 crossref_primary_10_1007_s12029_021_00714_x crossref_primary_10_3748_wjg_v27_i42_7271 crossref_primary_10_1111_jvh_13645 crossref_primary_10_1016_j_jhep_2023_02_041 crossref_primary_10_1007_s12072_022_10365_0 crossref_primary_10_1186_s12575_025_00269_2 crossref_primary_10_1016_j_jhep_2020_11_032 crossref_primary_10_3390_v16050740 crossref_primary_10_1056_NEJMe2304147 crossref_primary_10_17235_reed_2025_11393_2025 crossref_primary_10_1007_s00108_020_00923_9 crossref_primary_10_3390_v15122345 crossref_primary_10_3390_v16081254 crossref_primary_10_1038_s41598_023_37756_z crossref_primary_10_1097_CLD_0000000000000113 crossref_primary_10_1097_CM9_0000000000002011 crossref_primary_10_1080_14712598_2024_2313112 crossref_primary_10_1016_j_jhep_2022_06_010 crossref_primary_10_3390_v13081532 crossref_primary_10_5501_wjv_v13_i3_97973 crossref_primary_10_1111_liv_14838 crossref_primary_10_3390_pathogens11050517 crossref_primary_10_1002_rmv_2374 crossref_primary_10_1016_j_cgh_2023_04_022 crossref_primary_10_1038_s41598_024_69304_8 crossref_primary_10_1111_liv_14833 crossref_primary_10_1111_liv_15921 crossref_primary_10_1111_liv_14950 crossref_primary_10_1002_jmv_28634 crossref_primary_10_1136_gutjnl_2020_323888 crossref_primary_10_1093_jalm_jfaf092 crossref_primary_10_3390_pathogens14090941 crossref_primary_10_1111_jvh_70046 crossref_primary_10_1128_jcm_01999_24 crossref_primary_10_1111_tog_12989 crossref_primary_10_1159_000531773 crossref_primary_10_1136_egastro_2024_100067 crossref_primary_10_1371_journal_ppat_1012060 crossref_primary_10_1080_14728214_2022_2074977 crossref_primary_10_1093_ije_dyab049 crossref_primary_10_3390_v16081236 crossref_primary_10_1055_a_2133_8614 crossref_primary_10_1016_j_jhep_2024_11_051 crossref_primary_10_1016_j_clinre_2023_102148 crossref_primary_10_1016_j_jhepr_2025_101436 crossref_primary_10_1111_jvh_70033 crossref_primary_10_3390_cells12101413 crossref_primary_10_1080_0194262X_2022_2028698 crossref_primary_10_1111_jvh_70036 crossref_primary_10_1111_imj_15849 crossref_primary_10_1111_jvh_70029 crossref_primary_10_1007_s43472_025_00168_7 crossref_primary_10_1038_s41467_021_26475_6 crossref_primary_10_3390_v13122371 crossref_primary_10_1016_j_glmedi_2024_100058 crossref_primary_10_3390_ijms231810817 crossref_primary_10_3390_v17040568 crossref_primary_10_1111_jvh_70022 crossref_primary_10_1097_MD_0000000000026571 crossref_primary_10_3390_v13081572 crossref_primary_10_1097_HC9_0000000000000168 crossref_primary_10_3389_fmicb_2021_751531 crossref_primary_10_1097_HEP_0000000000000331 crossref_primary_10_3390_microorganisms12112177 crossref_primary_10_2147_DDDT_S379964 crossref_primary_10_1002_hep4_1685 crossref_primary_10_1016_j_jhep_2024_12_044 crossref_primary_10_1155_2024_6622276 crossref_primary_10_3390_v14071467 crossref_primary_10_1016_j_cld_2021_06_001 crossref_primary_10_3390_v16060992 crossref_primary_10_1128_AAC_01586_21 crossref_primary_10_1016_S1470_2045_25_00403_6 crossref_primary_10_1097_HEP_0000000000000584 crossref_primary_10_1128_spectrum_01447_22 crossref_primary_10_1111_jnc_70066 crossref_primary_10_1111_liv_15602 crossref_primary_10_1080_21642850_2023_2192782 crossref_primary_10_3390_v16050716 crossref_primary_10_4103_sjg_sjg_322_24 crossref_primary_10_1038_s41571_023_00825_3 crossref_primary_10_1016_j_jhep_2022_07_016 crossref_primary_10_1186_s13099_021_00462_0 crossref_primary_10_1016_j_jhep_2023_10_043 crossref_primary_10_1016_j_cld_2022_08_001 crossref_primary_10_2147_JEP_S235550 crossref_primary_10_5812_hepatmon_143785 crossref_primary_10_3390_jpm13060964 crossref_primary_10_1016_j_ijregi_2024_100560 crossref_primary_10_1055_a_1498_2512 crossref_primary_10_1136_sextrans_2024_056364 crossref_primary_10_1080_14787210_2023_2159379 crossref_primary_10_1111_liv_14967 crossref_primary_10_1097_TXD_0000000000001253 crossref_primary_10_1016_S2468_1253_20_30307_1 crossref_primary_10_4103_JME_JME_51_25 crossref_primary_10_1007_s10620_020_06584_w crossref_primary_10_1016_j_jhep_2023_08_002 crossref_primary_10_3389_fmed_2023_1355027 crossref_primary_10_1177_13596535211039589 crossref_primary_10_3390_life13122271 crossref_primary_10_3389_fpubh_2023_1247454 crossref_primary_10_3390_v14050986 crossref_primary_10_1097_HEP_0000000000000687 crossref_primary_10_1056_NEJMoa2314134 crossref_primary_10_1016_S1473_3099_22_00412_1 crossref_primary_10_3390_livers4030028 crossref_primary_10_1007_s00726_025_03465_2 crossref_primary_10_1186_s13104_022_05976_7 crossref_primary_10_1016_j_cld_2021_06_011 crossref_primary_10_1111_hepr_13936 crossref_primary_10_1097_CLD_0000000000000221 crossref_primary_10_1016_j_antiviral_2022_105461 crossref_primary_10_1016_j_ijid_2024_107115 crossref_primary_10_1016_j_gastrohep_2025_502337 crossref_primary_10_1016_j_ijregi_2025_100732 crossref_primary_10_3390_v16071044 crossref_primary_10_1097_MEG_0000000000002857 crossref_primary_10_3390_genes15080982 crossref_primary_10_3390_pathogens14090899 crossref_primary_10_3390_ijerph17207657 crossref_primary_10_3390_v12111334 crossref_primary_10_1016_j_jhep_2024_01_035 crossref_primary_10_1111_liv_16174 crossref_primary_10_4254_wjh_v17_i6_107963 crossref_primary_10_1016_j_ympev_2024_108114 crossref_primary_10_1097_HC9_0000000000000078 crossref_primary_10_1016_j_micpath_2025_107837 crossref_primary_10_3389_fmicb_2024_1472826 crossref_primary_10_52054_FVVO_2025_48 crossref_primary_10_1136_sextrans_2023_056098 crossref_primary_10_3390_v17050667 crossref_primary_10_1016_j_eimce_2024_09_006 crossref_primary_10_1007_s00103_021_03478_8 crossref_primary_10_1080_03007995_2024_2318004 crossref_primary_10_1016_j_jinf_2025_106514 crossref_primary_10_1111_apt_18446 crossref_primary_10_3390_pathogens13090793 crossref_primary_10_3390_v16111710 crossref_primary_10_1016_j_jcv_2024_105650 crossref_primary_10_1016_j_cld_2023_03_006 crossref_primary_10_1111_apt_70251 crossref_primary_10_1016_j_jhep_2022_05_022 crossref_primary_10_1016_j_jhep_2022_05_023 crossref_primary_10_1016_S2468_1253_22_00124_8 crossref_primary_10_3390_v16111723 crossref_primary_10_1371_journal_pone_0250347 crossref_primary_10_1016_j_ejogrb_2020_11_052 crossref_primary_10_1016_j_gastre_2022_09_001 crossref_primary_10_7759_cureus_43362 crossref_primary_10_1016_j_jhep_2021_10_012 crossref_primary_10_1016_j_jsps_2024_102126 crossref_primary_10_1111_liv_16031 crossref_primary_10_1128_spectrum_03965_22 crossref_primary_10_1016_j_advms_2025_07_003 crossref_primary_10_7759_cureus_79307 crossref_primary_10_1016_j_virol_2024_110273 crossref_primary_10_14309_ctg_0000000000000509 crossref_primary_10_1016_j_jhepr_2022_100461 crossref_primary_10_1016_j_virusres_2024_199451 crossref_primary_10_1097_MEG_0000000000002707 crossref_primary_10_1016_j_gastrohep_2024_502241 crossref_primary_10_3390_cells9061471 crossref_primary_10_1007_s00103_021_03479_7 crossref_primary_10_1055_a_2057_1840 crossref_primary_10_3390_microorganisms10112096 crossref_primary_10_1111_apt_18227 crossref_primary_10_2174_0109298673288458240203064112 crossref_primary_10_1016_j_lanwpc_2022_100468 crossref_primary_10_3390_cancers17030432 crossref_primary_10_1007_s12325_022_02070_z crossref_primary_10_1136_bmjopen_2022_067429 crossref_primary_10_14309_ajg_0000000000002153 crossref_primary_10_3390_microorganisms13010118 crossref_primary_10_1016_j_jhep_2023_05_001 crossref_primary_10_2196_37016 crossref_primary_10_3389_fimmu_2022_893512 crossref_primary_10_1007_s11901_024_00643_w crossref_primary_10_1097_HEP_0000000000001144 crossref_primary_10_1002_cld_1106 crossref_primary_10_3389_fmicb_2022_992817 crossref_primary_10_1016_j_jval_2024_06_002 crossref_primary_10_1016_j_gastre_2025_502241 crossref_primary_10_3390_cancers15020533 crossref_primary_10_3748_wjg_v28_i1_76 crossref_primary_10_1111_jvh_14021 crossref_primary_10_3138_canlivj_2025_0012_f crossref_primary_10_3138_canlivj_2025_0012_e crossref_primary_10_3390_antiox12040974 crossref_primary_10_1097_TP_0000000000004138 crossref_primary_10_1016_j_ijregi_2025_100590 crossref_primary_10_1016_j_jcv_2024_105689 crossref_primary_10_1007_s11901_024_00653_8 crossref_primary_10_1111_hiv_13518 crossref_primary_10_1016_j_jhep_2023_12_031 crossref_primary_10_1136_bmjgh_2021_007744 crossref_primary_10_1016_j_micpath_2025_107805 crossref_primary_10_3748_wjg_v28_i14_1405 crossref_primary_10_1016_j_gastre_2025_502337 crossref_primary_10_1093_cid_ciaf181 crossref_primary_10_1007_s40267_021_00843_0 crossref_primary_10_1016_S1473_3099_22_00318_8 crossref_primary_10_1016_j_revmed_2021_10_329 crossref_primary_10_1002_hep_32732 crossref_primary_10_1111_jvh_14043 crossref_primary_10_3390_microorganisms11071739 crossref_primary_10_3748_wjg_v27_i24_3556 crossref_primary_10_1111_jvh_14060 crossref_primary_10_7861_clinmed_2022_0556 crossref_primary_10_1111_apt_16485 crossref_primary_10_34084_bshr_1668347 crossref_primary_10_1186_s12879_023_08928_z |
| Cites_doi | 10.1053/j.gastro.2018.09.058 10.1016/S2468-1253(18)30056-6 10.1002/sim.791 10.1001/jamaoncol.2017.3055 10.1016/S0168-8278(17)30310-0 10.1016/S2214-109X(17)30298-X 10.1016/S0140-6736(15)61412-X 10.1016/S2468-1253(17)30288-1 10.1097/XEB.0000000000000054 10.1186/s12916-014-0145-y 10.1111/jvh.13081 10.1093/oxfordjournals.aje.a121617 10.1111/jvh.12947 10.1002/hep.28772 10.1016/j.jhep.2015.04.025 10.1002/sim.1009 10.1002/hep.28957 10.1128/JCM.03521-13 10.1136/gutjnl-2018-317403 10.1136/gutjnl-2018-317874 10.1136/gut.46.3.420 10.1186/s12985-017-0845-y 10.1016/S0140-6736(10)61931-9 |
| ContentType | Journal Article |
| Copyright | 2020 European Association for the Study of the Liver Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. 2020 European Association for the Study of the Liver. Published by Elsevier B.V. 2020 European Association for the Study of the Liver |
| Copyright_xml | – notice: 2020 European Association for the Study of the Liver – notice: Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. – notice: 2020 European Association for the Study of the Liver. Published by Elsevier B.V. 2020 European Association for the Study of the Liver |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1016/j.jhep.2020.04.008 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1600-0641 |
| EndPage | 532 |
| ExternalDocumentID | PMC7438974 32335166 10_1016_j_jhep_2020_04_008 S0168827820302208 |
| Genre | Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review Journal Article |
| GrantInformation_xml | – fundername: Wellcome Trust grantid: 109130/Z/15/Z – fundername: World Health Organization grantid: 001 |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29K 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 D-I DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDZ HMK HMO HVGLF HX~ HZ~ IHE J1W KOM LZ1 M27 M41 MJL MO0 N9A O-L O9- OAUVE OC. ON0 OVD OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K TEORI UV1 WUQ X7M YOC Z5R ZGI ~G- ~HD 6I. AACTN AAFTH AAIAV ABLVK ABYKQ AFCTW AFKWA AHPSJ AJBFU AJOXV AMFUW LCYCR RIG 9DU AAYXX CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c572t-4c83656fd9e6e5c98c18d19afa9a3258a6e162b34bfc8ddbb779c1ef22a978b3 |
| ISICitedReferencesCount | 473 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000562756400047&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0168-8278 1600-0641 |
| IngestDate | Tue Sep 30 16:45:12 EDT 2025 Wed Oct 01 13:57:21 EDT 2025 Mon Jul 21 06:06:25 EDT 2025 Tue Nov 18 22:02:17 EST 2025 Sat Nov 29 07:25:00 EST 2025 Fri Feb 23 02:47:28 EST 2024 Tue Oct 14 19:28:22 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Hepatocellular Carcinoma Prevalence Hepatitis D Liver cirrhosis Epidemiology Hepatitis delta virus Hepatitis B Meta-analysis |
| Language | English |
| License | This is an open access article under the CC BY license. Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c572t-4c83656fd9e6e5c98c18d19afa9a3258a6e162b34bfc8ddbb779c1ef22a978b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0003-0640-181X 0000-0003-2315-8954 0000-0002-3642-277X 0000-0003-1242-839X 0000-0002-5828-3328 0000-0002-2797-015X |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7438974 |
| PMID | 32335166 |
| PQID | 2395258909 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7438974 proquest_miscellaneous_2395258909 pubmed_primary_32335166 crossref_citationtrail_10_1016_j_jhep_2020_04_008 crossref_primary_10_1016_j_jhep_2020_04_008 elsevier_sciencedirect_doi_10_1016_j_jhep_2020_04_008 elsevier_clinicalkey_doi_10_1016_j_jhep_2020_04_008 |
| PublicationCentury | 2000 |
| PublicationDate | September 2020 2020-09-00 20200901 |
| PublicationDateYYYYMMDD | 2020-09-01 |
| PublicationDate_xml | – month: 09 year: 2020 text: September 2020 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Journal of hepatology |
| PublicationTitleAlternate | J Hepatol |
| PublicationYear | 2020 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Hughes, Wedemeyer, Harrison (bib5) 2011; 378 (bib13) 2012 Kushner, Serper, Kaplan (bib8) 2015; 63 Akinyemiju, Abera, Ahmed, Alam, Alemayohu, Allen (bib4) 2017; 3 Schwarzer (bib23) 2007; 7 Chen, Oidovsambuu, Liu, Grosely, Elazar, Winn (bib26) 2017; 66 Fattovich, Giustina, Christensen, Pantalena, Zagni, Realdi (bib7) 2000; 46 Koh, Heller, Glenn (bib10) 2018; 156 Munn, Moola, Lisy, Riitano, Tufanaru (bib14) 2015; 13 Lutterkort, Wranke, Hengst, Yurdaydin, Stift, Bremer (bib28) 2018; 25 Bazinet, Pântea, Cebotarescu, Cojuhari, Jimbei, Albrecht (bib32) 2017; 2 (bib18) 2019 Stockdale, Chaponda, Beloukas, Phillips, Matthews, Papadimitropoulos (bib11) 2017; 5 Botelho-Souza, Vasconcelos, Dos Santos, Salcedo, Vieira (bib6) 2017; 14 Hartung, Knapp (bib21) 2001; 20 Stockdale, Kreuels, Henrion, Giorgi, Kyomuhangi, Geretti (bib25) 2020; 69 Miettinen (bib19) 1974; 99 Brichler, Le Gal, Neri-Pinto, Mansour, Roulot, Laperche (bib12) 2014; 52 Wedemeyer, Schoeneweis, Bogomolov, Voronkova, Chulanov, Stepanova (bib31) 2018; 68 Le Gal, Brichler, Sahli, Chevret, Gordien (bib9) 2016; 64 (bib2) 2018; 3 (bib16) 2019 (bib27) 2016 Yurdaydin (bib29) 2019; 26 (bib17) 2017 Schweitzer, Horn, Mikolajczyk, Krause, Ott (bib20) 2015; 386 (bib1) 2017 Hartung, Knapp (bib22) 2001; 20 Wedemeyer, Port, Deterding, Wranke, Kirschner, Bruno (bib30) 2017; 66 Mokdad, Lopez, Shahraz, Lozano, Mokdad, Stanaway (bib3) 2014; 12 Brinkhoff (bib15) 2019 Wedemeyer, Negro (bib24) 2019; 68 Botelho-Souza (10.1016/j.jhep.2020.04.008_bib6) 2017; 14 Hartung (10.1016/j.jhep.2020.04.008_bib22) 2001; 20 Kushner (10.1016/j.jhep.2020.04.008_bib8) 2015; 63 Yurdaydin (10.1016/j.jhep.2020.04.008_bib29) 2019; 26 (10.1016/j.jhep.2020.04.008_bib17) 2017 Fattovich (10.1016/j.jhep.2020.04.008_bib7) 2000; 46 Stockdale (10.1016/j.jhep.2020.04.008_bib11) 2017; 5 Schwarzer (10.1016/j.jhep.2020.04.008_bib23) 2007; 7 Koh (10.1016/j.jhep.2020.04.008_bib10) 2018; 156 Le Gal (10.1016/j.jhep.2020.04.008_bib9) 2016; 64 Wedemeyer (10.1016/j.jhep.2020.04.008_bib24) 2019; 68 Akinyemiju (10.1016/j.jhep.2020.04.008_bib4) 2017; 3 Stockdale (10.1016/j.jhep.2020.04.008_bib25) 2020; 69 Bazinet (10.1016/j.jhep.2020.04.008_bib32) 2017; 2 Wedemeyer (10.1016/j.jhep.2020.04.008_bib30) 2017; 66 Mokdad (10.1016/j.jhep.2020.04.008_bib3) 2014; 12 (10.1016/j.jhep.2020.04.008_bib13) 2012 Chen (10.1016/j.jhep.2020.04.008_bib26) 2017; 66 (10.1016/j.jhep.2020.04.008_bib16) 2019 Wedemeyer (10.1016/j.jhep.2020.04.008_bib31) 2018; 68 Miettinen (10.1016/j.jhep.2020.04.008_bib19) 1974; 99 (10.1016/j.jhep.2020.04.008_bib1) 2017 Hughes (10.1016/j.jhep.2020.04.008_bib5) 2011; 378 Hartung (10.1016/j.jhep.2020.04.008_bib21) 2001; 20 (10.1016/j.jhep.2020.04.008_bib18) 2019 Munn (10.1016/j.jhep.2020.04.008_bib14) 2015; 13 Brichler (10.1016/j.jhep.2020.04.008_bib12) 2014; 52 Schweitzer (10.1016/j.jhep.2020.04.008_bib20) 2015; 386 (10.1016/j.jhep.2020.04.008_bib27) 2016 Brinkhoff (10.1016/j.jhep.2020.04.008_bib15) 2019 (10.1016/j.jhep.2020.04.008_bib2) 2018; 3 Lutterkort (10.1016/j.jhep.2020.04.008_bib28) 2018; 25 32863046 - J Hepatol. 2020 Nov;73(5):1280-1281. doi: 10.1016/j.jhep.2020.06.039. 32684365 - J Hepatol. 2020 Sep;73(3):493-495. doi: 10.1016/j.jhep.2020.06.037. 32829929 - J Hepatol. 2020 Nov;73(5):1279-1280. doi: 10.1016/j.jhep.2020.05.019. |
| References_xml | – volume: 14 start-page: 177 year: 2017 ident: bib6 article-title: Hepatitis delta: virological and clinical aspects publication-title: Virol J – volume: 26 start-page: 618 year: 2019 end-page: 626 ident: bib29 article-title: New treatment options for delta virus: is a cure in sight? publication-title: J Viral Hepat – year: 2012 ident: bib13 article-title: Development of a quality appraisal tool for case series studies using a modified Delphi technique – volume: 13 start-page: 147 year: 2015 end-page: 153 ident: bib14 article-title: Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data publication-title: Int J Evid Based Health Care – year: 2019 ident: bib15 article-title: City Population – volume: 12 start-page: 145 year: 2014 ident: bib3 article-title: Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis publication-title: BMC Med – volume: 68 start-page: 381 year: 2019 end-page: 382 ident: bib24 article-title: Devil hepatitis D: an orphan disease or largely underdiagnosed? publication-title: Gut – volume: 52 start-page: 1694 year: 2014 end-page: 1697 ident: bib12 article-title: Serological and molecular diagnosis of hepatitis delta virus infection: results of a French national quality control study publication-title: J Clin Microbiol – volume: 20 start-page: 1771 year: 2001 end-page: 1782 ident: bib21 article-title: On tests of the overall treatment effect in meta-analysis with normally distributed responses publication-title: Stat Med – volume: 66 start-page: 1739 year: 2017 end-page: 1749 ident: bib26 article-title: A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians publication-title: Hepatology – volume: 63 start-page: 586 year: 2015 end-page: 592 ident: bib8 article-title: Delta hepatitis within the veterans affairs medical system in the United States: prevalence, risk factors, and outcomes publication-title: J Hepatol – volume: 2 start-page: 877 year: 2017 end-page: 889 ident: bib32 article-title: Treatment of HBV/HDV co-infection with REP-2139 and pegylated interferon publication-title: Lancet Gastroenterol Hepatol – volume: 66 start-page: S24 year: 2017 ident: bib30 article-title: PS-039 - a phase 2 dose-escalation study of lonafarnib plus ritonavir in patients with chronic hepatitis D: final results from the Lonafarnib with ritonavir in HDV-4 (LOWR HDV-4) study publication-title: J Hepatol – year: 2019 ident: bib16 article-title: World Population Prospects – volume: 68 start-page: 11A year: 2018 ident: bib31 article-title: Interim results of a multicentre, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in combination with Peg-Interferon alpha 2a in patients with chronic HBV/HDV co-infection publication-title: Hepatology – volume: 3 start-page: 1683 year: 2017 end-page: 1691 ident: bib4 article-title: The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015 publication-title: JAMA Oncol – volume: 64 start-page: 1483 year: 2016 end-page: 1494 ident: bib9 article-title: First international external quality assessment for hepatitis delta virus RNA quantification in plasma publication-title: Hepatology – volume: 99 start-page: 325 year: 1974 end-page: 332 ident: bib19 article-title: Proportion of disease caused or prevented by a given exposure, trait or intervention publication-title: Am J Epidemiol – volume: 25 start-page: 1384 year: 2018 end-page: 1394 ident: bib28 article-title: Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy publication-title: J Viral Hepat – year: 2017 ident: bib17 article-title: Global and country estimates of immunization coverage and chronic HBV infection – volume: 3 start-page: 383 year: 2018 end-page: 403 ident: bib2 article-title: Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study publication-title: Lancet Gastroenterol Hepatol – volume: 5 start-page: e992 year: 2017 end-page: e1003 ident: bib11 article-title: Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis publication-title: Lancet Glob Health – volume: 378 start-page: 73 year: 2011 end-page: 85 ident: bib5 article-title: Hepatitis delta virus publication-title: Lancet – year: 2017 ident: bib1 article-title: Global Hepatitis Report – volume: 156 start-page: 461 year: 2018 end-page: 476 ident: bib10 article-title: Pathogenesis of and new therapies for hepatitis D publication-title: Gastroenterology – year: 2016 ident: bib27 article-title: Global health sector strategy on viral hepatitis 2016-2021 – volume: 69 start-page: 396 year: 2020 end-page: 397 ident: bib25 article-title: Hepatitis D prevalence: problems with extrapolation to global population estimates publication-title: Gut – volume: 386 start-page: 1546 year: 2015 end-page: 1555 ident: bib20 article-title: Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 publication-title: Lancet – volume: 20 start-page: 3875 year: 2001 end-page: 3889 ident: bib22 article-title: A refined method for the meta-analysis of controlled clinical trials with binary outcome publication-title: Stat Med – volume: 7 start-page: 40 year: 2007 end-page: 45 ident: bib23 article-title: Meta: an R package for meta-analysis publication-title: R News – year: 2019 ident: bib18 article-title: Consolidated strategic information guidelines for viral hepatitis: planning and tracking progress towards elimination – volume: 46 start-page: 420 year: 2000 end-page: 426 ident: bib7 article-title: Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep) publication-title: Gut – volume: 156 start-page: 461 year: 2018 ident: 10.1016/j.jhep.2020.04.008_bib10 article-title: Pathogenesis of and new therapies for hepatitis D publication-title: Gastroenterology doi: 10.1053/j.gastro.2018.09.058 – volume: 3 start-page: 383 year: 2018 ident: 10.1016/j.jhep.2020.04.008_bib2 article-title: Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(18)30056-6 – volume: 20 start-page: 1771 year: 2001 ident: 10.1016/j.jhep.2020.04.008_bib21 article-title: On tests of the overall treatment effect in meta-analysis with normally distributed responses publication-title: Stat Med doi: 10.1002/sim.791 – volume: 3 start-page: 1683 year: 2017 ident: 10.1016/j.jhep.2020.04.008_bib4 article-title: The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2017.3055 – volume: 66 start-page: S24 year: 2017 ident: 10.1016/j.jhep.2020.04.008_bib30 article-title: PS-039 - a phase 2 dose-escalation study of lonafarnib plus ritonavir in patients with chronic hepatitis D: final results from the Lonafarnib with ritonavir in HDV-4 (LOWR HDV-4) study publication-title: J Hepatol doi: 10.1016/S0168-8278(17)30310-0 – volume: 5 start-page: e992 year: 2017 ident: 10.1016/j.jhep.2020.04.008_bib11 article-title: Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(17)30298-X – year: 2019 ident: 10.1016/j.jhep.2020.04.008_bib16 – volume: 386 start-page: 1546 year: 2015 ident: 10.1016/j.jhep.2020.04.008_bib20 article-title: Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 publication-title: Lancet doi: 10.1016/S0140-6736(15)61412-X – volume: 2 start-page: 877 year: 2017 ident: 10.1016/j.jhep.2020.04.008_bib32 article-title: Treatment of HBV/HDV co-infection with REP-2139 and pegylated interferon publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(17)30288-1 – volume: 13 start-page: 147 year: 2015 ident: 10.1016/j.jhep.2020.04.008_bib14 article-title: Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data publication-title: Int J Evid Based Health Care doi: 10.1097/XEB.0000000000000054 – volume: 7 start-page: 40 year: 2007 ident: 10.1016/j.jhep.2020.04.008_bib23 article-title: Meta: an R package for meta-analysis publication-title: R News – volume: 12 start-page: 145 year: 2014 ident: 10.1016/j.jhep.2020.04.008_bib3 article-title: Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis publication-title: BMC Med doi: 10.1186/s12916-014-0145-y – volume: 26 start-page: 618 year: 2019 ident: 10.1016/j.jhep.2020.04.008_bib29 article-title: New treatment options for delta virus: is a cure in sight? publication-title: J Viral Hepat doi: 10.1111/jvh.13081 – year: 2012 ident: 10.1016/j.jhep.2020.04.008_bib13 – volume: 99 start-page: 325 year: 1974 ident: 10.1016/j.jhep.2020.04.008_bib19 article-title: Proportion of disease caused or prevented by a given exposure, trait or intervention publication-title: Am J Epidemiol doi: 10.1093/oxfordjournals.aje.a121617 – volume: 25 start-page: 1384 year: 2018 ident: 10.1016/j.jhep.2020.04.008_bib28 article-title: Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy publication-title: J Viral Hepat doi: 10.1111/jvh.12947 – volume: 64 start-page: 1483 year: 2016 ident: 10.1016/j.jhep.2020.04.008_bib9 article-title: First international external quality assessment for hepatitis delta virus RNA quantification in plasma publication-title: Hepatology doi: 10.1002/hep.28772 – volume: 63 start-page: 586 year: 2015 ident: 10.1016/j.jhep.2020.04.008_bib8 article-title: Delta hepatitis within the veterans affairs medical system in the United States: prevalence, risk factors, and outcomes publication-title: J Hepatol doi: 10.1016/j.jhep.2015.04.025 – volume: 20 start-page: 3875 year: 2001 ident: 10.1016/j.jhep.2020.04.008_bib22 article-title: A refined method for the meta-analysis of controlled clinical trials with binary outcome publication-title: Stat Med doi: 10.1002/sim.1009 – volume: 66 start-page: 1739 year: 2017 ident: 10.1016/j.jhep.2020.04.008_bib26 article-title: A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians publication-title: Hepatology doi: 10.1002/hep.28957 – year: 2017 ident: 10.1016/j.jhep.2020.04.008_bib1 – volume: 52 start-page: 1694 year: 2014 ident: 10.1016/j.jhep.2020.04.008_bib12 article-title: Serological and molecular diagnosis of hepatitis delta virus infection: results of a French national quality control study publication-title: J Clin Microbiol doi: 10.1128/JCM.03521-13 – year: 2019 ident: 10.1016/j.jhep.2020.04.008_bib15 – volume: 68 start-page: 381 year: 2019 ident: 10.1016/j.jhep.2020.04.008_bib24 article-title: Devil hepatitis D: an orphan disease or largely underdiagnosed? publication-title: Gut doi: 10.1136/gutjnl-2018-317403 – volume: 69 start-page: 396 year: 2020 ident: 10.1016/j.jhep.2020.04.008_bib25 article-title: Hepatitis D prevalence: problems with extrapolation to global population estimates publication-title: Gut doi: 10.1136/gutjnl-2018-317874 – year: 2019 ident: 10.1016/j.jhep.2020.04.008_bib18 – year: 2016 ident: 10.1016/j.jhep.2020.04.008_bib27 – volume: 46 start-page: 420 year: 2000 ident: 10.1016/j.jhep.2020.04.008_bib7 article-title: Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep) publication-title: Gut doi: 10.1136/gut.46.3.420 – volume: 14 start-page: 177 year: 2017 ident: 10.1016/j.jhep.2020.04.008_bib6 article-title: Hepatitis delta: virological and clinical aspects publication-title: Virol J doi: 10.1186/s12985-017-0845-y – volume: 378 start-page: 73 year: 2011 ident: 10.1016/j.jhep.2020.04.008_bib5 article-title: Hepatitis delta virus publication-title: Lancet doi: 10.1016/S0140-6736(10)61931-9 – volume: 68 start-page: 11A year: 2018 ident: 10.1016/j.jhep.2020.04.008_bib31 article-title: Interim results of a multicentre, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in combination with Peg-Interferon alpha 2a in patients with chronic HBV/HDV co-infection publication-title: Hepatology – year: 2017 ident: 10.1016/j.jhep.2020.04.008_bib17 – reference: 32684365 - J Hepatol. 2020 Sep;73(3):493-495. doi: 10.1016/j.jhep.2020.06.037. – reference: 32863046 - J Hepatol. 2020 Nov;73(5):1280-1281. doi: 10.1016/j.jhep.2020.06.039. – reference: 32829929 - J Hepatol. 2020 Nov;73(5):1279-1280. doi: 10.1016/j.jhep.2020.05.019. |
| SSID | ssj0003094 |
| Score | 2.7178166 |
| SecondaryResourceType | review_article |
| Snippet | There are uncertainties about the epidemic patterns of HDV infection and its contribution to the burden of liver disease. We estimated the global prevalence of... • HDV infection is common among HBsAg-positive people worldwide. • Among HBsAg-positive people, estimated HDV prevalence is 4.5% (95% CI 3.6–5.7). • HDV... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 523 |
| SubjectTerms | Adult Carcinoma Carcinoma, Hepatocellular - virology Coinfection - complications Coinfection - epidemiology Epidemiology Female Genotype Hepatitis Antibodies - blood Hepatitis B Hepatitis B - complications Hepatitis B - epidemiology Hepatitis B - virology Hepatitis B Surface Antigens Hepatitis B virus - immunology Hepatitis D Hepatitis D - blood Hepatitis D - complications Hepatitis D - epidemiology Hepatitis D - virology Hepatitis delta virus Hepatitis Delta Virus - genetics Hepatitis Delta Virus - immunology Hepatocellular Homosexuality, Male Humans Immunoglobulin G - blood Liver cirrhosis Liver Cirrhosis - virology Liver Neoplasms - virology Male Meta-analysis Prevalence Renal Dialysis - adverse effects RNA, Viral - genetics Sex Workers Sexual and Gender Minorities Substance Abuse, Intravenous - complications |
| Title | The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0168827820302208 https://dx.doi.org/10.1016/j.jhep.2020.04.008 https://www.ncbi.nlm.nih.gov/pubmed/32335166 https://www.proquest.com/docview/2395258909 https://pubmed.ncbi.nlm.nih.gov/PMC7438974 |
| Volume | 73 |
| WOSCitedRecordID | wos000562756400047&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1600-0641 dateEnd: 20210630 omitProxy: false ssIdentifier: ssj0003094 issn: 0168-8278 databaseCode: AIEXJ dateStart: 20200301 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Za9tAEF6cpIS8lN51j7CFvhkZS6vV7vYtJO4RmhAaU5wnoWOV2sSyUWSTv9Z_19lD6yMkPaAvwsgaeb3zaWZ2NPMtQu_B4lEJfsgLihQWKBGVXpomkZcXoaSUJyLRb0y_f2Wnp3w4FGet1s-mF2ZxxcqS39yI2X9VNZwDZavW2b9Qt7spnIDPoHQ4gtrh-MeKtzQfs0qReetnV8eEqnq6Hl13jjqLUTVfVmLp6o7zDU5nUyo8kXXiJZa55I5IVt94LT1_XoOZbUqVXQ9N57jr7Hsl5-CVNbrA1E-XKdmyGtmCfsUicNH95mQ-jabVpS4-6E-SEsTlasoC1qdNTZbNo1mnv5rWjLjHA7OZT1caUxypnvfI0GI1ttpse2IxSVYMLzVdy9aHU5MzveUeTKZi3B3DxHTVyDTNrSaWqFegMZtobJCAEOpHG0zd2vefnRwytW88C7fQTsCoAIO6c_ClPzx2YQDpCUssb_6a7dgyxYWbA9hDu82v3RUg3V4AbdbxrgRGg0foocUBPjBIfIxasnyCdk9szcZTdAGAxAaQeAlIPC2wAyQ-whqQ2AHyA17CERs4YsAQXoPjMzT42B8cfvbshh5eRllQe2HGCawfilzISNJM8MznuS-SAkwCCcAyRNKPgpSEaZHxPE9TxkTmyyIIEsF4Sp6j7XJaypcIs9yHhQTzKQOj0hN5CivxUEQFlynLciLbyG8mMc4s2b3ac-Uqbqoax7HSQax0EPfCGHTQRh0nMzNUL_deTRrdxE0TM7jdGKB2rxR1UjbENaHrb-XeNeqPwf6rl3pJKafz6zgggsLUiZ5ooxcGDm70DaTaiK0BxV2guOXXvylHPzTHvEX3q3-WfI32lo_-G7RdV3P5Fj3IFoCqah9tsSHft4_ML844-Cc |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+global+prevalence+of+hepatitis+D+virus+infection%3A+Systematic+review+and+meta-analysis&rft.jtitle=Journal+of+hepatology&rft.au=Stockdale%2C+Alexander+J.&rft.au=Kreuels%2C+Benno&rft.au=Henrion%2C+Marc+Y.R.&rft.au=Giorgi%2C+Emanuele&rft.date=2020-09-01&rft.pub=Elsevier&rft.issn=0168-8278&rft.eissn=1600-0641&rft.volume=73&rft.issue=3&rft.spage=523&rft.epage=532&rft_id=info:doi/10.1016%2Fj.jhep.2020.04.008&rft_id=info%3Apmid%2F32335166&rft.externalDocID=PMC7438974 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0168-8278&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0168-8278&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0168-8278&client=summon |